All In Biotech

Drug Trial Radar · NCT04435652

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel for Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine

Last checked: Nov 19, 2026Latest source record: Jun 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 492 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

492

Planned (sponsor's estimate)

Start

Jul 1, 2020

Primary completion

Apr 30, 2022

Study completion Nov 30, 2022

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who had tumor progression after first-line treatment with platinum and fluoropyrimidine doublet therapy. The study will be conducted in 2 parts.

Conditions

  • Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

  • QL1604Drug

    3mg/kg, D1,8,15,Q4w, IV infusion

  • Nab-paclitaxelDrug

    100mg/m2, D1,8,15,Q4w, IV infusion

  • PaclitaxelDrug

    80mg/m2, D1,8,15,Q4w, IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and severity of adverse events (AE) and serious adverse events (SAE) according to CTCAE V5.0Time frame: Up to 90 days from last dose
  2. The percentages of participants discontinuing or suspending the study drug due to an AE.Time frame: Up to 90 days from last dose
  3. Overall survival(OS)(stage 2)Time frame: from the date of first dose until the date of death from any cause,assessed up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Cancer Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.